Employees: 28
Size Opus Genetics (IRD) is a United States Health Care company (Pharmaceuticals: Major) with a market value of $379M, the 2877th largest of 3,085 United States companies the cockpit tracks. Shares closed at $3.92 on 18 Nov 2026.
Performance Over six months the shares fell 22.1%, against -22.7% for the median peer and -2.2% for the United States market (cap-weighted) — 10th highest of 19 in its peer set.
Growth Revenue fell 45.9% over the last twelve months (peer median +3.0%); the operating margin is -777.7% (peer median -2.2%).
Valuation It trades at 41.2× enterprise value to sales against a peer median of 4.4× (3rd most expensive of 18).
Next results Next results expected around 11 Mar 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | $7.91M | $14.2M | $11.0M | $19.0M | $39.9M |
| Revenue growth | — | +29% | -42% | -52% | — |
| Gross profit | $7.85M | $14.1M | $11.0M | $19.0M | $39.8M |
| EBITDA | -$61.5M | -$38.5M | -$34.1M | -$10.6M | $18.2M |
| Net income | -$137M | -$49.6M | -$57.5M | -$9.99M | $17.9M |
| Free cash flow | -$48.7M | -$35.3M | -$25.6M | -$1.11M | $14.3M |
| Capital expenditure | $189,000 | $0 | $0 | $0 | $0 |
| Total debt | $35.9M | $1.13M | $18.8M | $0 | $0 |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | IRD | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -2.2% | -14.0% | 3rd highest of 20 |
| 6-month return | -22.1% | -22.7% | 10th highest of 19 |
| Distance from 52-week high | -32.5% | -43.3% | 8th highest of 21 |
| Revenue growth (TTM) | -45.9% | +3.0% | 2nd lowest of 18 |
| Operating margin | -777.7% | -2.2% | 3rd lowest of 19 |
| EV / Sales | 41.2× | 4.4× | 3rd most expensive of 18 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Opus Genetics IRD | United States | $379M | -22% | -46% | -778% | 41.2× | n/a | n/a |
| JCR Pharmaceuticals 4552.T | Japan | $379M | -5% | +3% | -14% | 2.9× | n/a | n/a |
| Jiangsu Bioperfectus Technologies 688399.SS | China | $374M | -51% | -8% | -23% | 4.4× | n/a | n/a |
| Lifecome Biochemistry 002868.SZ | China | $384M | -54% | -23% | -3% | 6.2× | n/a | n/a |
| Puma Biotechnology PBYI | United States | $373M | +3% | +9% | 11% | 1.2× | 0.1% | +0.3% |
| SanBio 4592.T | Japan | $386M | -55% | n/a | n/a | n/a | n/a | n/a |
| Gansu Longshenrongfa Pharmaceutical Industry 300534.SZ | China | $386M | -2% | -21% | 8% | 3.7× | 20.9% | +28.2% |
| Shukra Pharmaceuticals SHUKRAPHAR.NS | India | $387M | n/a | +222% | 54% | 32.0× | n/a | n/a |
| iX Biopharma 42C.SI | Singapore | $387M | +28% | -12% | -140% | 71.6× | n/a | n/a |
| ARS Pharmaceuticals SPRY | United States | $371M | -53% | -14% | -162% | 2.9× | n/a | n/a |
| Tiansheng Pharmaceutical 002872.SZ | China | $371M | -1% | -1% | -13% | 4.9× | 22.2% | -15.7% |
| Avalo Therapeutics AVTX | United States | $387M | -59% | -69% | -161,961% | n/a | n/a | n/a |
| Anhui Sunhere Pharmaceutical Excipients 300452.SZ | China | $388M | -17% | +9% | 19% | 2.2× | -5.5% | +12.2% |
| MapLight Therapeutics MPLT | United States | $370M | -76% | n/a | n/a | n/a | n/a | n/a |
| 6467 6467.TW | Taiwan | $368M | n/a | n/a | -2,618% | 1,407.9× | n/a | n/a |
| Guangdong Lifestrong Pharmacy 301111.SZ | China | $368M | -33% | +7% | -2% | 7.2× | n/a | n/a |
| Heartseed 219A.T | Japan | $392M | +53% | +197% | 9% | 21.9× | 46.5% | +73.2% |
| Pharmicell 005690.KS | South Korea | $364M | -55% | +46% | 32% | 3.0× | -7.9% | +24.8% |
| Tuoxin Pharmaceutical 301089.SZ | China | $363M | -28% | +17% | -20% | 5.3× | n/a | n/a |
| Unichem Laboratories UNICHEMLAB.NS | India | $361M | +28% | +6% | 5% | 1.6× | n/a | n/a |
| Jiangxi Synergy Pharmaceutical 300636.SZ | China | $398M | -13% | -3% | 2% | 3.4× | 14.9% | +13.7% |